UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 12, 2011

Streamline Health Solutions, Inc.

(Exact name of registrant as specified in its charter)

Delaware		0-28132	31-1455414							
	(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)							
	10200 Alliance Road, Suite 200, Cin	cinnati, OH	45242-4716							
	(Address of principal executive	offices)	(Zip Code)							
	Registrant's telephone number, including area code: (513) 794-7100 (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant									
unu	er any of the following provisions:									
0	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)									
О	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)									
0	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))									
0	Pre-commencement communications pu	rsuant to Rule 13e-4(c) under the Ex	change Act (17 CFR 240.13e-4(c))							

Item 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On September 12, 2011, Streamline Health Solutions, Inc. ("Streamline Health") issued the press release attached hereto as Exhibit 99.1, which press release contains financial information about Streamline Health's second fiscal quarter ended July 31, 2011. The information hereunder shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

EXHIBIT NUMBER

DESCRIPTION

99.1 Second Quarter Earnings News Release of Streamline Health Solutions, Inc. dated September 12, 2011.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Streamline Health Solutions, Inc.

Date: September 12, 2011 By: /s/ Stephen H. Murdock

Stephen H. Murdock Chief Financial Officer

2

INDEX TO EXHIBITS

Exhibit No. Description of Exhibit

99.1 Second Quarter Earnings News Release of Streamline Health Solutions, Inc. dated September 12, 2011.



News Release

Visit our web site at: www.streamlinehealth.net

COMPANY CONTACT: Robert E. Watson Chief Executive Officer (513) 794-7100 INVESTOR CONTACT: Joe Diaz, Robert Blum or Joe Dorame Lytham Partners, LLC (602) 889-9700

STREAMLINE HEALTH® SOLUTIONS REPORTS Q2 RESULTS

Cincinnati, Ohio — September 12, 2011 — Streamline Health Solutions, Inc. (Nasdaq: STRM) today announced financial results for the second quarter of fiscal year 2011, ended July 31, 2011.

Highlights for the quarter and the six-month period included:

- Recurring maintenance revenues improved by 16% over the prior comparable quarter;
- Recurring software-as-a-service (SaaS) revenues for the quarter increased 3% over the prior comparable quarter;
- New bookings for the quarter, excluding maintenance revenue, exceeded \$1.8 million;
- Backlog at quarter end was \$18.1 million;
- Adjusted EBITDA on a year-to-date basis increased 100%;
- In August 2011, St. Vincent's Medical Center extended its agreement with Streamline Health's strategic partner, GE Healthcare. Under the terms of the seven-year agreement, the healthcare system will be converting from a licensing model to Streamline Health's SaaS model, and will upgrade to a new accessANYware version with additional HIM workflows;

Revenues for the second quarter totaled \$4.1 million, compared to \$4.7 million in the prior year second quarter, the decrease in revenue is primarily the result of two large proprietary license sales that were recognized in the second quarter of fiscal 2010, that did not have comparable sales in the current quarter.

Recurring revenues from maintenance contracts improved by 16% or \$300,000 over the prior comparable second quarter. The increase is due to the continued revenue recognition from backlog, and the incremental maintenance revenues from systems sold in prior quarters for which maintenance periods commenced subsequent to their respective sales in prior quarters. SaaS revenues increased by \$29,000 or 3% over the prior comparable quarter due to one large customer subscription sold in fiscal 2010 which reached go-live status in fiscal 2011.

Total operating expenses for the second quarter of fiscal 2011 were \$4.1 million compared with \$4.7 million in the comparable prior year quarter. This decrease of approximately \$600,000 was the result of management's action to implement more sustainable staffing levels, processes, and costs; these reductions coupled with decreased capitalized software amortization due to older assets becoming fully amortized subsequent to the first half of fiscal 2010.

As a result, the Company recorded a net loss for the second quarter ended July 31, 2011 of \$7,000, or \$0.00 per fully diluted share, compared with net loss of \$76,000, or \$0.01 per fully diluted share, for the prior year comparable quarter. Adjusted EBITDA* (a non-GAAP measure) for the quarter ended July 31, 2011 was \$919,000, or \$0.09 per fully diluted common share (adjusted), compared to \$990,000, or \$0.10 per fully diluted common share (adjusted) in the comparable prior quarter. A reconciliation table is provided below.

New bookings for the second quarter, excluding maintenance services, were \$1.9 million, primarily consisting of SaaS term fees and professional services.

Backlog at July 31, 2011 was \$18.1 million, compared with \$18.9 million at July 31, 2010 and \$17.6 million at January 31, 2011. The decrease in the current backlog reflects recognition of revenue from SaaS and maintenance contracts in the prior backlog and the addition to the backlog of new maintenance, software and professional services contracts sold in the quarters subsequent to July 31, 2010.

Robert E. Watson, president and chief executive officer of Streamline Health said, "While revenues are up slightly on a year-to-date basis, adjusted EBITDA for the six month period is up 100% versus the comparable period last year. That is meaningful progress despite the dual burden of high severance costs and the costs to bring on-board the appropriate executives and associates as we continue to reposition this company to achieve material annual growth rates consistent with other high growth healthcare information technology companies. As I've indicated previously this is a process and we are moving along that continuum at a consistent rate. I am pleased with the progress this new management team has made in the two quarters of its tenure."

Mr. Watson continued, "We are also pleased with the transitioning of the University of Virginia Health System to a "direct client" of Streamline Health coupled with their purchase of additional workflow technology, and the transitioning of St. Vincent's Medical Center from a maintenance client to a long term SaaS client. This strongly reflects the new commitment of our sales force to gain a deeper understanding of our clients and to present solutions on how we might better meet their needs. In conjunction with a strong focus on managing operating expenses, we are making meaningful progress in recalibrating Streamline Health to become a leading healthcare information technology company."

* Non-GAAP Financial Measures

Streamline Health reports its financial results in accordance with generally accepted accounting principles in the United States ("GAAP"). Streamline Health's management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline Health's management believes that these measures provide useful supplemental information regarding the performance of Streamline Health's business operations.

Streamline Health defines "adjusted EBITDA" as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, and stock-based compensation expense. A table illustrating this measure is included in this publication.

Conference Call Information

The Company will conduct a conference call and webcast to review the results of the second quarter of fiscal 2011 today, September 12, 2011, at 4:30 p.m. ET.

Interested parties can access the call by dialing (877) 317-6789 or (412) 317-6789, or listen via a live Internet webcast, which can be found at www.streamlinehealth.net. A replay of the call will be available for 30 days by visiting www.streamlinehealth.net or by calling (877) 344-7529 or (412) 317-0088, access code 451358, through October 12, 2011.

About Streamline Health

Streamline Health is a leading provider of document workflow and document management solutions, applications and services that help strategic business partners and healthcare organizations improve operational efficiencies through business process optimization. The Company provides integrated tools and technologies for automating document-intensive environments, including document workflow, document management, e-forms, connectivity, optical character recognition (OCR), and business process integration.

The Company's workflow-based services offer solutions to inefficient and labor-intensive healthcare business processes throughout the revenue cycle, such as chart coding, abstracting and completion, remote physician referral order processing, pre-admission registration scanning and signature capture, financial screening, perioperative processing, mitigation processing, secondary billing services, explanation of benefits processing, and release of information processing. The Company's solutions also address the document workflow needs of the Human Resources and Supply Chain Management processes of the healthcare enterprise. All solutions are available through a software as a service (SaaS) model of delivery via the Company's Remote Hosting Center that better matches customers' capital or operating budget needs, or via a locally installed software licensing model.

Streamline Health's solutions create a permanent document-based repository of historical health information that is complementary and can be seamlessly integrated with existing disparate clinical, financial and administrative information systems, providing convenient electronic access to multiple forms of patient information from any location through secure web-based access. These integrated solutions allow providers and administrators to link existing systems with documents, which can dramatically improve the availability of patient information while decreasing direct costs associated with document retrieval, work-in-process, chart processing, document retention, and archiving.

For additional information please visit our website at www.streamlinehealth.net.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995

Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to risks and uncertainties. The forward looking statements contained herein are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements, included herein. These risks and uncertainties include, but are not limited to, the impact of competitive products and pricing, product demand and market acceptance, new product development, key strategic alliances with vendors that resell the Company products, the ability of the Company to control costs, availability of products produced from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accountings Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry, the markets in which the Company operates and nationally, and the Company's ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U. S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward looking statements, which reflect management's analysis only as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Financial Tables on Following Pages

STREAMLINE HEALTH SOLUTIONS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Three and Six Months Ended July 31, (Unaudited)

	Three Months				Six Months			
		2011		2010		2011		2010
Revenues:								
Systems sales	\$	163,200	\$	960,880	\$	294,202	\$	1,111,318
Services, maintenance and support		3,069,869		2,830,935		6,153,830		5,374,510
Software as a service		912,864		884,662	_	1,837,923		1,734,665
Total revenues (1)	_	4,145,933	_	4,676,477		8,285,955	_	8,220,493
Operating expenses:								
Cost of systems sales		627,550		780,506		1,168,502		1,518,395
Cost of services, maintenance and support		1,155,667		1,378,778		2,489,538		2,760,988
Cost of software as a service		417,868		472,098		854,291		929,126
Selling, general and administrative		1,582,532		1,505,863		3,247,193		3,203,440
Product research and development		342,157		567,147		759,931		1,037,318
Total operating expenses		4,125,774		4,704,392		8,519,455		9,449,267
Operating income (loss)		20,159		(27,915)		(233,500)		(1,228,774)
Other income (expense):								
Interest expense		(21,791)		(34,001)		(41,633)		(56,336)
Miscellaneous income (expenses)		(311)		(9,023)		(5,266)		42,786
Loss before income taxes		(1,943)		(70,939)		(280,399)		(1,242,324)
Income tax (expense)		(5,000)		(5,000)		(7,315)		(10,000)
Net loss	\$	(6,943)	\$	(75,939)	\$	(287,714)	\$	(1,252,324)
Basic and diluted net earnings (loss) per common share	\$	(0.00)	\$	(0.01)	\$	(0.03)	\$	(0.13)
Number of shares used in basic and diluted per common								
share computation		9,817,370	_	9,506,904	_	9,847,348	_	9,460,911

⁽¹⁾ Software as a service was previously labeled "Application hosting services", management determined that "Software as a service" more closely defines the Company's service offering.

STREAMLINE HEALTH SOLUTIONS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS

Assets

	(Unaudited) July 31, 2011	(Audited) January 31, 2011		
Current assets:				
Cash and cash equivalents	\$ 577,885	\$ 1,403,949		
Accounts receivable, net of allowance for doubtful accounts of \$140,000 and \$100,000,				
respectively	2,151,458	2,620,756		
Contract receivables	535,941	680,096		
Prepaid hardware and third party software for future delivery	40,963	72,259		
Prepaid customer maintenance contracts	925,667	794,299		
Other prepaid assets	217,187	200,056		
Deferred income taxes	167,000	167,000		
Total current assets	4,616,101	5,938,415		
Property and equipment:				
Computer equipment	2,815,087	2,708,819		
Computer software	2,037,063	1,947,135		
Office furniture, fixtures and equipment	747,867	747,867		
Leasehold improvements	639,864	639,864		
	6,239,881	6,043,685		
Accumulated depreciation and amortization	(4,895,412)	(4,517,860)		
	1,344,469	1,525,825		
Other assets:	1,544,405	1,323,023		
	274.647	241 742		
Contract receivables, less current portion	274,647	241,742		
Capitalized software development costs, net of accumulated amortization of \$13,833,284	7.005.107	7 575 064		
and \$12,832,347, respectively	7,965,127	7,575,064		
Other, including deferred taxes of \$711,000, respectively	738,475	734,376		
Total other assets	8,978,249	8,551,182		
Liabilities and Stockholders' Equity	\$ 14,938,819	\$ 16,015,422		
	(Unaudited) July 31, 2011	(Audited) January 31, 2011		
Current liabilities:				
Accounts payable	\$ 752,454	\$ 565,252		
Accrued compensation	575,603	1,163,843		
Accrued other expenses	285,215	480,422		
Capital lease obligation	132,299	183,637		
Deferred revenues	5,093,616	5,766,795		
Total current liabilities	6,839,187	8,159,949		
Long-term liabilities:				
Line of credit	1,250,000	1,200,000		
Lease incentive liability, less current portion	54,464	61,034		
Total liabilities	8,143,651	9,420,983		
	0,145,051	3,420,303		
Stockholders' equity:				
Convertible redeemable preferred stock, \$.01 par value per share, 5,000,000 shares authorized, no shares issued	_	_		
Common stock, \$.01 par value per share, 25,000,000 shares authorized, 10,053,979 and				
9,856,517 shares issued and outstanding, respectively	100,539	98,565		
Additional paid in capital	37,461,711	36,975,242		
Accumulated deficit	(30,767,082)	(30,479,368)		
Total stockholders' equity	6,795,168	6,594,439		
	\$ 14,938,819	\$ 16,015,422		

STREAMLINE HEALTH SOLUTIONS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Six Months Ended, (Unaudited)

Operating activities: S (287,714) \$ (1,252,324) Net loss \$ (287,714) \$ (1,252,324) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: \$ (2,667) \$ (1,08,706) Depreciation and amortization 1,391,822 1,708,706 Loss on disposal of fixed asset 28,667 \$ (2,607) Stock-based compensation expense 395,732 243,104 Provision for accounts receivable 40,000 50,000 Change in assets and liabilities: \$ 540,548 (133,787) Accounts, contract and installment receivables 540,548 (133,787) Other assets (121,302) (114,459) Accounts payable 187,002 200,007 Accounts payable 187,002 200,007 Accounts payable 6673,179 (328,530) Net cash provided by (used in) operating activities 709,759 (15,333) Investing activities: 2 2 (236,196) (302,292) Capitalization of software development costs (1,627,196) (1,573,318) Vet cash used in investing activities </th <th></th> <th>July 31, 2011</th> <th>July 31, 2010</th>		July 31, 2011	July 31, 2010
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation and amortization 1,391,822 1,708,706 Loss on disposal of fixed asset 26,667 — Stock-based compensation expense 395,732 243,104 Provision for accounts receivable 40,000 50,000 Change in assets and liabilities: 540,548 (133,787) Other assets (121,302) (114,459) Accounts payable 187,202 200,007 Accrued expenses (790,017) (388,100) Deferred revenues (673,179) (328,530) Net cash provided by (used in) operating activities 709,759 (15,383) Investing activities: V V Purchases of property and equipment (236,196) (302,292) Capitalization of software development costs (1,391,000) (1,274,000) Other — 2,974 Net cash used in investing activities 50,000 1,100,000 Financing activities: S 50,000 1,100,000 Proceeds from exercise of stock options and stock purchase plan 92,711 127,391	Operating activities:		
Depreciation and amortization 1,391,822 1,708,706 Loss on disposal of fixed asset 26,667 — Stock-based compensation expense 395,732 243,104 Provision for accounts receivable 40,000 50,000 Change in assets and liabilities: *** *** Accounts, contract and installment receivables 540,548 (133,787) Other assets (121,302) (114,459) Accounts payable 187,202 200,007 Accrued expenses (790,017) (388,100) Deferred revenues (673,179) (328,530) Net cash provided by (used in) operating activities 709,759 (15,383) Investing activities: ** ** Purchases of property and equipment (236,196) (302,292) Capitalization of software development costs (1,391,000) (1,274,000) Other ** 2,974 Net cash used in investing activities ** ** Financing activities: ** ** Net cash used in investing activities 50,000 1,100,000	Net loss	\$ (287,714)	\$ (1,252,324)
Loss on disposal of fixed asset 26,667 — Stock-based compensation expense 395,732 243,104 Provision for accounts receivable 40,000 50,000 Change in assets and liabilities: **** Accounts, contract and installment receivables \$40,548 (133,787) Other assets (121,302) (114,459) Accounts payable 187,202 200,007 Accrued expenses (790,017) (388,100) Deferred revenues (673,179) (328,530) Net cash provided by (used in) operating activities *** 709,759 (15,338) Investing activities: *** *** 200,007 (328,530) (302,292) Capitalization of software development costs (1,331,000) (1,574,000) (1,274,000) (1,274,000) (1,274,000) (1,274,000) (1,274,000) (1,274,000) (1,274,000) (1,274,000) (1,273,318) ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** <td>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</td> <td></td> <td></td>	Adjustments to reconcile net loss to net cash provided by (used in) operating activities:		
Stock-based compensation expense 395,732 243,104 Provision for accounts receivable 40,000 50,000 Change in assets and liabilities: 340,548 (133,787) Other assets (121,302) (114,459) Accounts payable 187,202 200,007 Accrued expenses (673,179) (328,530) Net cash provided by (used in) operating activities 709,759 (15,333) Investing activities: 2 (236,196) (302,292) Capitalization of software development costs (1,391,000) (1,274,000) Other — 2,974 Net cash used in investing activities (1,627,196) (1,573,318) Financing activities: 50,000 1,100,000 Proceeds from exercise of stock options and stock purchase plan 92,711 127,391 Payments on capital lease obligation (51,338) (83,289) Net cash provided by financing activities 91,373 1,144,102 Decrease in cash and cash equivalents (826,064) (444,599) Cash and cash equivalents at beginning of period 1,403,949	Depreciation and amortization	1,391,822	1,708,706
Provision for accounts receivable 40,000 50,000 Change in assets and liabilities: 540,548 (133,787) Accounts, contract and installment receivables 540,548 (133,787) Other assets (121,302) (114,459) Accounts payable 187,202 200,007 Accrued expenses (790,017) (388,100) Deferred revenues (673,179) (328,530) Net cash provided by (used in) operating activities 709,759 (15,383) Investing activities: Variation of software development costs (1,391,000) (1,274,000) Other — — 2,974 Net cash used in investing activities (1,627,196) (1,573,318) Financing activities: Stonation of the contractivities of the con		26,667	_
Change in assets and liabilities: 540,548 (133,787) Other assets (121,302) (114,459) Accounts payable 187,202 200,007 Accrued expenses (790,017) (388,100) Deferred revenues (673,179) (328,530) Net cash provided by (used in) operating activities 709,759 (15,383) Investing activities: Variable of the control of software development costs (1,391,000) (1,274,000) Other — 2,974 Net cash used in investing activities (1,627,196) (1,573,318) Financing activities: Variable of the control of software development costs (1,627,196) (1,573,318) Financing activities: Variable of the control of software development costs (1,627,196) (1,573,318) Financing activities: Variable of the control of software development costs (1,627,196) (1,573,318) Financing activities: Variable of the control		395,732	243,104
Accounts, contract and installment receivables 540,548 (133,787) Other assets (121,302) (114,459) Accounts payable 187,202 200,007 Accrued expenses (790,017) (388,100) Deferred revenues (673,179) (328,530) Net cash provided by (used in) operating activities 709,759 (15,383) Investing activities: 2 (236,196) (302,292) Capitalization of software development costs (1,391,000) (1,274,000) Other — 2,974 Net cash used in investing activities (1,627,196) (1,573,318) Financing activities: 50,000 1,100,000 Proceeds from exercise of stock options and stock purchase plan 92,711 127,391 Payments on capital lease obligation (51,338) (83,289) Net cash provided by financing activities 91,373 1,144,102 Decrease in cash and cash equivalents (826,064) (444,599) Cash and cash equivalents at beginning of period 5,77,885 \$80,574 Supplemental cash flow disclosures: 1,025,173 <td></td> <td>40,000</td> <td>50,000</td>		40,000	50,000
Other assets (121,302) (114,459) Accounts payable 187,202 200,007 Accrued expenses (790,017) (388,100) Deferred revenues (673,179) (328,530) Net cash provided by (used in) operating activities 709,759 (15,383) Investing activities: 236,196 (302,292) Capitalization of software development costs (1,391,000) (1,274,000) Other — 2,974 Net cash used in investing activities (1,627,196) (1,573,318) Financing activities: Strangent of the control of t	Change in assets and liabilities:		
Accounts payable 187,202 200,007 Accrued expenses (790,017) (388,100) Deferred revenues (673,179) (328,530) Net cash provided by (used in) operating activities 709,759 (15,383) Investing activities: 2 Variable of property and equipment (236,196) (302,292) Capitalization of software development costs (1,391,000) (1,274,000) Other — 2,974 Net cash used in investing activities (1,627,196) (1,573,318) Financing activities: Variable of the contractivities of the contractivity of the contractivities of the contractivities of the contracti	Accounts, contract and installment receivables	540,548	(133,787)
Accrued expenses (790,017) (388,100) Deferred revenues (673,179) (328,530) Net cash provided by (used in) operating activities 709,759 (15,383) Investing activities: 2 2 Purchases of property and equipment (236,196) (302,292) Capitalization of software development costs (1,391,000) (1,274,000) Other — 2,974 Net cash used in investing activities (1,627,196) (1,573,318) Financing activities: Standard activities: Standard activities: Net change under revolving credit facility 50,000 1,100,000 Proceeds from exercise of stock options and stock purchase plan 92,711 127,391 Payments on capital lease obligation (51,338) (83,289) Net cash provided by financing activities 91,373 1,144,102 Decrease in cash and cash equivalents (826,064) (444,599) Cash and cash equivalents at beginning of period 1,403,949 1,025,173 Cash and cash equivalents at end of period \$77,885 \$80,574 Supplemental cash flow disclosures:	Other assets	(121,302)	(114,459)
Deferred revenues (673,179) (328,530) Net cash provided by (used in) operating activities 709,759 (15,383) Investing activities: \$\$\$\$\$ (236,196) (302,292) Capitalization of software development costs (1,391,000) (1,274,000) Other - 2,974 Net cash used in investing activities (1,627,196) (1,573,318) Financing activities: \$		187,202	
Net cash provided by (used in) operating activities 709,759 (15,383) Investing activities: 236,196 (302,292) Purchases of property and equipment (1,391,000) (1,274,000) Other — 2,974 Net cash used in investing activities (1,627,196) (1,573,318) Financing activities: Secondary of the control	•	· , ,	
Investing activities: Purchases of property and equipment (236,196) (302,292) Capitalization of software development costs (1,391,000) (1,274,000) Other — 2,974 Net cash used in investing activities (1,627,196) (1,573,318) Financing activities: Step change under revolving credit facility 50,000 1,100,000 Proceeds from exercise of stock options and stock purchase plan 92,711 127,391 Payments on capital lease obligation (51,338) (83,289) Net cash provided by financing activities 91,373 1,144,102 Decrease in cash and cash equivalents (826,064) (444,599) Cash and cash equivalents at beginning of period 1,403,949 1,025,173 Cash and cash equivalents at end of period \$ 577,885 \$ 580,574 Supplemental cash flow disclosures: 1 29,621 \$ 30,664	Deferred revenues	(673,179)	(328,530)
Purchases of property and equipment (236,196) (302,292) Capitalization of software development costs (1,391,000) (1,274,000) Other — 2,974 Net cash used in investing activities (1,627,196) (1,573,318) Financing activities: Net change under revolving credit facility 50,000 1,100,000 Proceeds from exercise of stock options and stock purchase plan 92,711 127,391 Payments on capital lease obligation (51,338) (83,289) Net cash provided by financing activities 91,373 1,144,102 Decrease in cash and cash equivalents (826,064) (444,599) Cash and cash equivalents at beginning of period 1,403,949 1,025,173 Cash and cash equivalents at end of period \$577,885 \$580,574 Supplemental cash flow disclosures: Interest paid \$29,621 \$30,664	Net cash provided by (used in) operating activities	709,759	(15,383)
Purchases of property and equipment (236,196) (302,292) Capitalization of software development costs (1,391,000) (1,274,000) Other — 2,974 Net cash used in investing activities (1,627,196) (1,573,318) Financing activities: Net change under revolving credit facility 50,000 1,100,000 Proceeds from exercise of stock options and stock purchase plan 92,711 127,391 Payments on capital lease obligation (51,338) (83,289) Net cash provided by financing activities 91,373 1,144,102 Decrease in cash and cash equivalents (826,064) (444,599) Cash and cash equivalents at beginning of period 1,403,949 1,025,173 Cash and cash equivalents at end of period \$577,885 \$580,574 Supplemental cash flow disclosures: Interest paid \$29,621 \$30,664			
Capitalization of software development costs (1,391,000) (1,274,000) Other — 2,974 Net cash used in investing activities (1,627,196) (1,573,318) Financing activities: Net change under revolving credit facility 50,000 1,100,000 Proceeds from exercise of stock options and stock purchase plan 92,711 127,391 Payments on capital lease obligation (51,338) (83,289) Net cash provided by financing activities 91,373 1,144,102 Decrease in cash and cash equivalents (826,064) (444,599) Cash and cash equivalents at beginning of period 1,403,949 1,025,173 Cash and cash equivalents at end of period \$ 577,885 \$ 580,574 Supplemental cash flow disclosures: \$ 29,621 \$ 30,664	Investing activities:		
Other — 2,974 Net cash used in investing activities (1,627,196) (1,573,318) Financing activities: Net change under revolving credit facility 50,000 1,100,000 Proceeds from exercise of stock options and stock purchase plan 92,711 127,391 Payments on capital lease obligation (51,338) (83,289) Net cash provided by financing activities 91,373 1,144,102 Decrease in cash and cash equivalents (826,064) (444,599) Cash and cash equivalents at beginning of period 1,403,949 1,025,173 Cash and cash equivalents at end of period \$ 577,885 \$ 580,574 Supplemental cash flow disclosures: Interest paid \$ 29,621 \$ 30,664	Purchases of property and equipment	(236,196)	(302,292)
Net cash used in investing activities (1,627,196) (1,573,318) Financing activities: Second 1,100,000 1,100,000 Proceeds from exercise of stock options and stock purchase plan 92,711 127,391 Payments on capital lease obligation (51,338) (83,289) Net cash provided by financing activities 91,373 1,144,102 Decrease in cash and cash equivalents (826,064) (444,599) Cash and cash equivalents at beginning of period 1,403,949 1,025,173 Cash and cash equivalents at end of period \$577,885 \$580,574 Supplemental cash flow disclosures: Interest paid \$29,621 \$30,664	Capitalization of software development costs	(1,391,000)	(1,274,000)
Financing activities: Net change under revolving credit facility Proceeds from exercise of stock options and stock purchase plan Payments on capital lease obligation Net cash provided by financing activities Pecrease in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental cash flow disclosures: Interest paid Sound 1,100,000 1,100,000 1,27,391 1	Other	_	2,974
Financing activities: Net change under revolving credit facility Proceeds from exercise of stock options and stock purchase plan Payments on capital lease obligation Net cash provided by financing activities Pecrease in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental cash flow disclosures: Interest paid Sound 1,100,000 1,100,000 1,27,391 1	Net cash used in investing activities	(1,627,196)	(1,573,318)
Net change under revolving credit facility 50,000 1,100,000 Proceeds from exercise of stock options and stock purchase plan 92,711 127,391 Payments on capital lease obligation (51,338) (83,289) Net cash provided by financing activities 91,373 1,144,102 Decrease in cash and cash equivalents (826,064) (444,599) Cash and cash equivalents at beginning of period 1,403,949 1,025,173 Cash and cash equivalents at end of period \$ 577,885 \$ 580,574 Supplemental cash flow disclosures: Interest paid \$ 29,621 \$ 30,664			
Proceeds from exercise of stock options and stock purchase plan 92,711 127,391 Payments on capital lease obligation (51,338) (83,289) Net cash provided by financing activities 91,373 1,144,102 Decrease in cash and cash equivalents (826,064) (444,599) Cash and cash equivalents at beginning of period 1,403,949 1,025,173 Cash and cash equivalents at end of period \$ 577,885 \$ 580,574 Supplemental cash flow disclosures: Interest paid \$ 29,621 \$ 30,664	Financing activities:		
Payments on capital lease obligation (51,338) (83,289) Net cash provided by financing activities 91,373 1,144,102 Decrease in cash and cash equivalents (826,064) (444,599) Cash and cash equivalents at beginning of period 1,403,949 1,025,173 Cash and cash equivalents at end of period \$ 577,885 \$ 580,574 Supplemental cash flow disclosures: Interest paid \$ 29,621 \$ 30,664	Net change under revolving credit facility	50,000	1,100,000
Net cash provided by financing activities 91,373 1,144,102 Decrease in cash and cash equivalents (826,064) (444,599) Cash and cash equivalents at beginning of period 1,403,949 1,025,173 Cash and cash equivalents at end of period \$ 577,885 \$ 580,574 Supplemental cash flow disclosures: Interest paid \$ 29,621 \$ 30,664	Proceeds from exercise of stock options and stock purchase plan	92,711	127,391
Decrease in cash and cash equivalents (826,064) (444,599) Cash and cash equivalents at beginning of period 1,403,949 1,025,173 Cash and cash equivalents at end of period \$ 577,885 \$ 580,574 Supplemental cash flow disclosures: \$ 29,621 \$ 30,664 Interest paid \$ 29,621 \$ 30,664	Payments on capital lease obligation	(51,338)	(83,289)
Cash and cash equivalents at beginning of period1,403,9491,025,173Cash and cash equivalents at end of period\$ 577,885\$ 580,574Supplemental cash flow disclosures:Interest paid\$ 29,621\$ 30,664	Net cash provided by financing activities	91,373	1,144,102
Cash and cash equivalents at beginning of period1,403,9491,025,173Cash and cash equivalents at end of period\$ 577,885\$ 580,574Supplemental cash flow disclosures:Interest paid\$ 29,621\$ 30,664	Decrease in cash and cash equivalents	(826,064)	(444,599)
Cash and cash equivalents at end of period \$577,885 \$580,574 Supplemental cash flow disclosures: Interest paid \$29,621 \$30,664			
Supplemental cash flow disclosures: Interest paid \$ 29,621 \$ 30,664			
Interest paid <u>\$ 29,621</u> <u>\$ 30,664</u>	·		
		\$ 29.621	\$ 30.664
Income taxes paid \$ 16,957 \$ 16,534	-		
	income taxes paid	\$ 16,957	\$ 16,534

STREAMLINE HEALTH SOLUTIONS, INC.

Backlog (Unaudited) **Table A**

Backlog (in thousands)

	July 31, 2011	January 31, 2011		July 31, 2010	
Streamline Health Software Licenses	\$ 51,000	\$	121,000	\$	174,000
Custom Software	29,000		42,000		62,000
Hardware and Third Party Software	152,000		66,000		95,000
Professional Services	4,573,000		4,629,000		3,981,000
Software as a service	7,275,000		7,362,000		8,818,000
Recurring Maintenance	6,009,000		5,384,000		5,788,000
Total	\$ 18,089,000	\$	17,604,000	\$	18,918,000

STREAMLINE HEALTH SOLUTIONS, INC.

Bookings (Unaudited) **Table B**

New bookings (a)

	11	July 31, 2011			
	Value	% of Total Bookings			
Streamline Health Software licenses	\$				
Software as a service	980,0	00 52%			
Professional services	792,0	00 42%			
Hardware & third party software	110,0	00 6%			
Total bookings	\$ 1,882,0	00 100%			

Six Months Ended July 31, 2011 Value % of Total Bookings Streamline Health Software licenses 40% Software as a service 1,067,000 Professional services 51% 1,358,000 Hardware & third party software 232,000 9% Total bookings \$ 2,657,000 100%

⁽a) Bookings are the aggregate of signed contracts and/or completed customer purchase orders approved and accepted by the Company as binding commitments to purchase its products and/or services. New bookings do not include maintenance services as these tend to be recurring in nature on an annual or more frequent basis.

STREAMLINE HEALTH SOLUTIONS, INC. Reconciliation of Non-GAAP Financial Measures (Unaudited)

Table C

This press release contains a non-GAAP financial measure under the rules of the U.S. Securities and Exchange Commission for adjusted EBITDA. This non-GAAP information supplements and is not intended to represent a measure of performance in accordance with disclosures required by generally accepted accounting principles. Non-GAAP financial measures are used internally to manage the business, such as in establishing an annual operating budget. Non-GAAP financial measures are used by Streamline Health's management in its operating and financial decision-making because management believes these measures reflect ongoing business in a manner that allows meaningful period-to-period comparisons. Accordingly, the Company believes it is useful for investors and others to review both GAAP and non-GAAP measures in order to (a) understand and evaluate current operating performance and future prospects in the same manner as management does and (b) compare in a consistent manner the company's current financial results with past financial results. The primary limitations associated with the use of non-GAAP financial measures are that these measures may not be directly comparable to the amounts reported by other companies and they do not include all items of income and expense that affect operations. The Company's management compensates for these limitations by considering the company's financial results and outlook as determined in accordance with GAAP and by providing a detailed reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures in the tables attached to this press release.

Reconciliation of net earnings(loss) to non-GAAP adjusted EBITDA (in thousands)

	Three Months Ended,			Six Months Ended,					
Adjusted EBITDA Reconciliation		July 31, 2011		July 31, 2010		July 31, 2011		July 31, 2010	
Net loss	\$	(7)	\$	(76)	\$	(288)	\$	(1,252)	
Interest expense		22		34		42		56	
Tax expenses		5		5		7		10	
Depreciation and other amortization		193		233		391		455	
Amortization of capitalized software development									
costs		507		639		1,001		1,254	
EBITDA		720		835		1,153		523	
Stock-based compensation expense		199		155		396		243	
Adjusted EBITDA	\$	919	\$	990	\$	1,549	\$	766	
Capitalized software development costs		606		578		1,391		1,274	
Adjusted EBITDA, less capitalized software									
development costs		313		412		158		(508)	
Adjusted EBITDA Margin		22%		21%		19%		9%	
Adjusted EBITDA per diluted share									
Earnings (loss) per share — diluted	\$	(0.00)	\$	(0.01)	\$	(0.03)	\$	(0.13)	
Interest expense (1)		0.00		0.00		0.00		0.00	
Tax expenses (1)		0.00		0.00		0.00		0.00	
Depreciation and other amortization (1)		0.02		0.02		0.04		0.05	
Amortization of capitalized software development									
costs (1)		0.05		0.07		0.10		0.13	
Stock-based compensation expense (1)		0.02		0.02		0.04		0.03	
Adjusted EBITDA per adjusted diluted share	\$	0.09	\$	0.10	\$	0.15	\$	0.08	
Diluted weighted average shares		9,817,370		9,506,904		9,847,348		9,460,911	
Includable incremental shares — adjusted EBITDA									
(2)		12,715		19,336		17,951		19,336	
Adjusted diluted shares	\$	9,830,085	\$	9,526,240		9,865,299		9,480,247	

- (1) Per adjusted diluted weighted average shares
- (2) The number of incremental shares that would be dilutive under profit assumption, only applicable under a GAAP net loss. If GAAP profit is earned in the current period, no additional incremental shares are assumed. If negative adjusted EBITDA is incurred, no additional incremental shares are assumed for adjusted diluted shares.